Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinomas: Does the Regimen Matter? Abstract #1778

Introduction: Metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare disease and the most effective chemotherapy regimen is debated, i.e. small cell lung carcinoma (SCLC) or non-small cell lung carcinoma (NSCLC) chemotherapy.
Aim(s): To analyze chemotherapeutic treatment for LCNEC on a population basis.
Materials and methods: The Netherlands pathology registry (PALGA) and cancer registry (IKNL) were searched for patients with LCNEC diagnosed between 2003-2012. In 207 patients tumour slides were available for panel-revision. Data on clinical characteristics and chemotherapy were retrieved. First-line platinum combined chemotherapy was clustered: 1) gemcitabine, docetaxel, paclitaxel or vinorelbine as NSCLC type, 2) pemetrexed as pem-NSCLC type, and 3) etoposide as SCLC type.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Jules Derks
Keywords: lcnec, chemotherapy, nec, lung

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1184 A National Pathology Registration Analysis of Applied Terminology in Pulmonary Neuroendocrine Tumors/Carcinomas: Is the WHO 2004 Classification in Line with Clinical Practice?
Introduction: Nomenclature of the WHO 2004 should be used for pulmonary neuro-endocrine tumors (NET) and carcinomas (NEC) classification.
Conference: 12th Annual ENETS Conference (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Jules Derks
Keywords: NET, Diagnosis
#2151 Therapeutic Efficacy of Platinum/Etoposide Regimens in the Treatment of Advanced Poor Differentiated Neuroendocrine Carcinomas of the Lung: A Retrospective Analysis
Introduction: Advanced neuroendocrine carcinomas (NEC) of the lung are associated with a dismal prognosis and are commonly treated with platinum/etoposide (P/E) regimens. However, few studies evaluated their impact in lung NEC and it is still unclear whether the outcome of such patients (pts) has been improved over the past years (yrs).
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Professor Vincenzo Adamo
#1192 Clinical Characteristics and Overall Survival of Large Cell Neuroendocrine Carcinoma (LCNEC) Compared to Other Subtypes of Lung Cancer: Results of a Population-based Registry
Introduction: LCNEC is a rare non-small cell lung cancer subtype and clinical behavior is unclear.
Conference: 12th Annual ENETS Conference (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Jules Derks
Keywords: LCNEC, lung
#2267 Large Cell Neuroendocrine Carcinoma of the Lung: Single-Centre Retrospective Cohort Study
Introduction: Large Cell Neuroendocrine Carcinoma (LCNEC) is a rare lung tumour, diagnosed based on high-grade features, presence of neuroendocrine morphology and immunohistochemical evidence of neuroendocrine markers. LCNEC was grouped with the pulmonary neuroendocrine carcinomas in 2015 WHO classification.
Conference: 15th Annual ENETS conference (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Dr Diogo Martins Branco
Keywords: LCNEC
#653 Interobserver Variability of Pulmonary Carcinoids
Introduction: Lung carcinoids are neuroendocrine tumors histopathologically classified into typical (TC; no necrosis, <2 mitoses/2 mm2) and atypical (AC; necrosis or 2-10 mitoses/2 mm2). Identification of mitoses may be hampered by the presence of apoptotic cells, and reported prediction of prognosis based on histopathology varies, especially for ACs.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MSc Dorian Swarts